MedCity News September 5, 2024
Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. Lilly is trying to catch up to Novo Nordisk’s once weekly insulin icodec, which is commercially available in several markets around the world but is not yet approved by the FDA.
An Eli Lilly insulin engineered for once-weekly dosing now has preliminary results from two more pivotal studies showing the injection was comparable to once-daily insulin, a new slate of data that brings the experimental insulin closer to competing with a Novo Nordisk product that’s already commercially available in some parts of the world.
The Lilly insulin, efsitora alfa, is a fusion protein engineered to provide patients with...
Today's Sponsors
Today's Sponsor